A new easy to use rapid test for the diagnosis of acute COVID-19 infection


Actim Oy -developed  antigen test receives CE marking

The Finnish diagnostics company Actim Oy has recently received a CE mark for the new Actim SARS-CoV-2 rapid test. The test is intended for healthcare professionals and it detects the nucleoprotein of SARS-CoV-2 virus in the nasopharyngeal swab sample. The test has been shown to perform reliably with different variants of the coronavirus, such as the UK, Indian, and South African virus variants.

Actim SARS-CoV-2 is a user-friendly, one-step dipstick test that gives test results in 15 minutes on site with no need for laboratory equipment. The test is specific for the novel coronavirus and does not cross-react with common viruses, such as other coronaviruses (229E, OC43), type A or B Influenza, or enteroviruses. It provides 98 % (Ct <30) sensitivity and 100 % specificity ensuring highly reliable, rapid, and accurate testing of current coronavirus infection.

“Reliable testing remains a critical step in controlling the novel COVID-19 pandemic and we are very proud to be able to offer an accurate and effective test that has outstanding sensitivity and specificity of 98% and 100% respectively. A first-class product, developed by a first-class team,” concludes Magnus Pålsson, the Managing Director of Actim Oy.

About Actim Oy

Actim Oy specializes in developing and producing innovative diagnostic rapid tests for healthcare. The high-quality products are designed with nearly 30 years of experience to meet the highest international standards. Actim tests can be used at the point of care and they are trusted by healthcare professionals worldwide. Actim is a part of Finnish biotechnology group Medix Biochemica.

For further information, please contact

Magnus Påhlsson
Managing Director
+358 50 470 0148